Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando Cabanillas

Showing results (51-60 of 102) with videos related to

Pageof 11
Sort By:
Puerto Rico Health Sciences Journal|October 8, 2020
Gastric MALT Lymphoma with Biclonal Gammopathy and Bone Marrow Involvement Mimicking Multiple MyelomaWilliam Cáceres-Perkins, Fernando Cabanillas, Glorivette San Vicente, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2003
Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphomaGeorge Z Rassidakis, Andre Goy, L Jeffrey Medeiros, et al.
International Journal of Radiation Oncology, Biology, Physics|September 6, 2003
Central lymphatic irradiation for stage I-III follicular lymphoma: report from a single-institutional prospective studyChul S Ha, Joseph S Kong, Susan L Tucker, et al.
Cancer|November 1, 2008
Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphomaMichael Wang, Luis Fayad, Fernando Cabanillas, et al.
Seminars in Oncology|February 1, 2017
Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasoneAndreas H Sarris, Yunfang Jiang, Apostolia M Tsimberidou, et al.
Boletin De La Asociacion Medica De Puerto Rico|January 9, 2016
Metastatic Ovarian Tumor Masquerading as Atypical PneumoniaIvonne Robles Cartagena, América Robles Cartagena, Glorilee Delgado Flores, et al.
Medrxiv : the Preprint Server for Health Sciences|March 24, 2021
Single-Arm, Open-Label Phase 2 Trial of Preemptive Methylprednisolone to Avert Progression to Respiratory Failure in High-Risk Patients with COVID-19Fernando Cabanillas, Javier Morales, José G Conde, et al.
Seminars in Oncology|February 14, 2002
Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasoneAndreas H Sarris, Yunfang Jiang, Apostolia M Tsimberidou, et al.
Puerto Rico Health Sciences Journal|June 11, 2024
Clinical Features and Therapeutic Outcomes Comparing Primary Mediastinal Large B-cell Lymphoma to Mediastinal Hodgkin DiseaseRubén J Cruz-Chamorro, Joshua L Rodríguez-López, Michael J González-Soto, et al.
Cancer|June 11, 2005
Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimenApostolia-Maria Tsimberidou, Anas Younes, Jorge Romaguera, et al.
Pageof 11

Showing results (51-60 of 102) with videos related to

Sort By:
Pageof 11
Puerto Rico Health Sciences Journal|October 8, 2020
Gastric MALT Lymphoma with Biclonal Gammopathy and Bone Marrow Involvement Mimicking Multiple MyelomaWilliam Cáceres-Perkins, Fernando Cabanillas, Glorivette San Vicente, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2003
Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphomaGeorge Z Rassidakis, Andre Goy, L Jeffrey Medeiros, et al.
International Journal of Radiation Oncology, Biology, Physics|September 6, 2003
Central lymphatic irradiation for stage I-III follicular lymphoma: report from a single-institutional prospective studyChul S Ha, Joseph S Kong, Susan L Tucker, et al.
Cancer|November 1, 2008
Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphomaMichael Wang, Luis Fayad, Fernando Cabanillas, et al.
Seminars in Oncology|February 1, 2017
Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasoneAndreas H Sarris, Yunfang Jiang, Apostolia M Tsimberidou, et al.
Boletin De La Asociacion Medica De Puerto Rico|January 9, 2016
Metastatic Ovarian Tumor Masquerading as Atypical PneumoniaIvonne Robles Cartagena, América Robles Cartagena, Glorilee Delgado Flores, et al.
Medrxiv : the Preprint Server for Health Sciences|March 24, 2021
Single-Arm, Open-Label Phase 2 Trial of Preemptive Methylprednisolone to Avert Progression to Respiratory Failure in High-Risk Patients with COVID-19Fernando Cabanillas, Javier Morales, José G Conde, et al.
Seminars in Oncology|February 14, 2002
Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasoneAndreas H Sarris, Yunfang Jiang, Apostolia M Tsimberidou, et al.
Puerto Rico Health Sciences Journal|June 11, 2024
Clinical Features and Therapeutic Outcomes Comparing Primary Mediastinal Large B-cell Lymphoma to Mediastinal Hodgkin DiseaseRubén J Cruz-Chamorro, Joshua L Rodríguez-López, Michael J González-Soto, et al.
Cancer|June 11, 2005
Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimenApostolia-Maria Tsimberidou, Anas Younes, Jorge Romaguera, et al.
Pageof 11